Key Points
- Regeneron EVP Marion McCourt sold 1,131 shares for approximately $969,708 at an average price of $857.39, reducing her holdings by 8.61% to 12,003 shares. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, and she also sold 1,215 shares the previous day.
- Regeneron reported quarterly EPS of $14.29, exceeding estimates of $10.16, while revenue rose 16.7% year over year to $4.29 billion. The company also declared a $0.94 quarterly dividend, equivalent to a 0.4% annual yield.
- Analysts maintain a “Moderate Buy” consensus, with 14 Buy and 10 Hold ratings and an average price target of $800.36. However, investors face potential litigation and reputational risks tied to allegations about disclosures surrounding the failed Phase 3 Fianlimab-Libtayo melanoma trial.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the sale, the director owned 603 shares in the company, valued at $512,550. This represents a 39.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kathryn Guarini also recently made the following trade(s):
- On Monday, August 10th, Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00.
Regeneron Pharmaceuticals Price Performance
REGN opened at $843.47 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $541.00 and a twelve month high of $859.34. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The firm has a market cap of $86.84 billion, a price-to-earnings ratio of 20.85, a PEG ratio of 1.67 and a beta of 0.20. The company has a fifty day simple moving average of $734.39 and a 200 day simple moving average of $719.34.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts' consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to analysts' expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm's revenue for the quarter was up 16.7% on a year-over-year basis. During the same period in the prior year, the company posted $12.81 EPS. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.
Regeneron Pharmaceuticals Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were paid a $0.94 dividend. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. Regeneron Pharmaceuticals's payout ratio is 9.29%.
Hedge Funds Weigh In On Regeneron Pharmaceuticals
Hedge funds have recently bought and sold shares of the company. Amundi increased its holdings in Regeneron Pharmaceuticals by 0.4% in the second quarter. Amundi now owns 1,013,540 shares of the biopharmaceutical company's stock valued at $631,983,000 after buying an additional 3,742 shares during the last quarter. HighTower Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 9.7% during the 2nd quarter. HighTower Advisors LLC now owns 64,650 shares of the biopharmaceutical company's stock worth $40,312,000 after buying an additional 5,725 shares during the last quarter. Groupe la Francaise lifted its holdings in Regeneron Pharmaceuticals by 25.1% during the 2nd quarter. Groupe la Francaise now owns 553 shares of the biopharmaceutical company's stock worth $321,000 after buying an additional 111 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $15,884,000. Finally, California State Teachers Retirement System grew its position in shares of Regeneron Pharmaceuticals by 63,274.2% in the 2nd quarter. California State Teachers Retirement System now owns 97,723,683 shares of the biopharmaceutical company's stock worth $60,934,625,000 after acquiring an additional 97,569,482 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.
Regeneron Pharmaceuticals News Summary
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: Regeneron reported that a Phase 1/2 study combining cemiplimab with SNS-101 has reached completion. The update provides a development milestone, although no efficacy or regulatory data were disclosed, limiting its immediate impact. Regeneron’s Cemiplimab Combo Trial With SNS-101 Reaches Completion
- Neutral Sentiment: Industry research projects substantial growth in the global complement-inhibitor market through 2035 and lists Regeneron among the leading companies. The report supports the company’s long-term opportunity but does not provide a new company-specific catalyst. 2026 Complement Inhibitors Market Analysis Report
- Negative Sentiment: Multiple law firms announced or promoted securities class actions involving investors who purchased REGN shares between August 1, 2025, and May 15, 2026. The lawsuits allege that Regeneron and certain executives misrepresented risks surrounding the Phase 3 Fianlimab-Libtayo melanoma trial, including a protocol change and eventual failure to meet its primary endpoint. Investors have until September 14, 2026, to seek lead-plaintiff status. The legal claims may increase reputational, litigation, and potential financial risks, although the allegations have not been proven. Hagens Berman Regeneron Securities Fraud Class Action Alert Robbins Geller Regeneron Investor Alert
- Negative Sentiment: Director Kathryn Guarini and EVP Marion McCourt reported sales totaling roughly $2.34 million. All transactions were executed under pre-arranged Rule 10b5-1 plans, reducing their significance as discretionary bearish signals, but the sales can still weigh on sentiment near the stock’s recent highs. SEC insider transaction filing
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on the company. Piper Sandler lowered their price objective on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating for the company in a research note on Thursday, July 9th. Leerink Partners upped their target price on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a "market perform" rating in a research report on Monday, August 17th. Wall Street Zen upgraded Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 15th. Royal Bank Of Canada raised their price target on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a "sector perform" rating in a research report on Friday, July 31st. Finally, HSBC dropped their price target on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a "buy" rating for the company in a research note on Monday, July 6th. Fourteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $800.36.
Check Out Our Latest Stock Analysis on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Company Profile
(
Get Free Report)
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
